These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. The mechanism of flecainide action in CPVT does not involve a direct effect on RyR2. Bannister ML; Thomas NL; Sikkel MB; Mukherjee S; Maxwell C; MacLeod KT; George CH; Williams AJ Circ Res; 2015 Apr; 116(8):1324-35. PubMed ID: 25648700 [TBL] [Abstract][Full Text] [Related]
5. RYR2 Channel Inhibition Is the Principal Mechanism of Flecainide Action in CPVT. Kryshtal DO; Blackwell DJ; Egly CL; Smith AN; Batiste SM; Johnston JN; Laver DR; Knollmann BC Circ Res; 2021 Feb; 128(3):321-331. PubMed ID: 33297863 [TBL] [Abstract][Full Text] [Related]
6. Moving in the right direction: elucidating the mechanisms of interaction between flecainide and the cardiac ryanodine receptor. Bannister ML; MacLeod KT; George CH Br J Pharmacol; 2022 Jun; 179(11):2558-2563. PubMed ID: 34698387 [TBL] [Abstract][Full Text] [Related]
7. Inhibition of cardiac Ca2+ release channels (RyR2) determines efficacy of class I antiarrhythmic drugs in catecholaminergic polymorphic ventricular tachycardia. Hwang HS; Hasdemir C; Laver D; Mehra D; Turhan K; Faggioni M; Yin H; Knollmann BC Circ Arrhythm Electrophysiol; 2011 Apr; 4(2):128-35. PubMed ID: 21270101 [TBL] [Abstract][Full Text] [Related]
8. How does flecainide impact RyR2 channel function? Salvage SC; Huang CL; Fraser JA; Dulhunty AF J Gen Physiol; 2022 Sep; 154(9):. PubMed ID: 35713932 [TBL] [Abstract][Full Text] [Related]
9. Insights on the mechanism of flecainide in catecholaminergic polymorphic ventricular tachycardia. Davidson R; Medeiros M J Med Life; 2023 Aug; 16(8):1294-1296. PubMed ID: 38024821 [TBL] [Abstract][Full Text] [Related]
10. Flecainide inhibits arrhythmogenic Ca2+ waves by open state block of ryanodine receptor Ca2+ release channels and reduction of Ca2+ spark mass. Hilliard FA; Steele DS; Laver D; Yang Z; Le Marchand SJ; Chopra N; Piston DW; Huke S; Knollmann BC J Mol Cell Cardiol; 2010 Feb; 48(2):293-301. PubMed ID: 19835880 [TBL] [Abstract][Full Text] [Related]
11. Short communication: flecainide exerts an antiarrhythmic effect in a mouse model of catecholaminergic polymorphic ventricular tachycardia by increasing the threshold for triggered activity. Liu N; Denegri M; Ruan Y; Avelino-Cruz JE; Perissi A; Negri S; Napolitano C; Coetzee WA; Boyden PA; Priori SG Circ Res; 2011 Jul; 109(3):291-5. PubMed ID: 21680895 [TBL] [Abstract][Full Text] [Related]
12. In silico prediction of drug therapy in catecholaminergic polymorphic ventricular tachycardia. Yang PC; Moreno JD; Miyake CY; Vaughn-Behrens SB; Jeng MT; Grandi E; Wehrens XH; Noskov SY; Clancy CE J Physiol; 2016 Feb; 594(3):567-93. PubMed ID: 26515697 [TBL] [Abstract][Full Text] [Related]
14. Effect of flecainide derivatives on sarcoplasmic reticulum calcium release suggests a lack of direct action on the cardiac ryanodine receptor. Bannister ML; Alvarez-Laviada A; Thomas NL; Mason SA; Coleman S; du Plessis CL; Moran AT; Neill-Hall D; Osman H; Bagley MC; MacLeod KT; George CH; Williams AJ Br J Pharmacol; 2016 Aug; 173(15):2446-59. PubMed ID: 27237957 [TBL] [Abstract][Full Text] [Related]
15. Arrhythmogenesis in a catecholaminergic polymorphic ventricular tachycardia mutation that depresses ryanodine receptor function. Zhao YT; Valdivia CR; Gurrola GB; Powers PP; Willis BC; Moss RL; Jalife J; Valdivia HH Proc Natl Acad Sci U S A; 2015 Mar; 112(13):E1669-77. PubMed ID: 25775566 [TBL] [Abstract][Full Text] [Related]
18. Flecainide therapy reduces exercise-induced ventricular arrhythmias in patients with catecholaminergic polymorphic ventricular tachycardia. van der Werf C; Kannankeril PJ; Sacher F; Krahn AD; Viskin S; Leenhardt A; Shimizu W; Sumitomo N; Fish FA; Bhuiyan ZA; Willems AR; van der Veen MJ; Watanabe H; Laborderie J; Haïssaguerre M; Knollmann BC; Wilde AA J Am Coll Cardiol; 2011 May; 57(22):2244-54. PubMed ID: 21616285 [TBL] [Abstract][Full Text] [Related]
19. The direct actions of flecainide on the human cardiac ryanodine receptor: keeping open the debate on the mechanism of action of local anesthetics in CPVT. Smith GL; MacQuaide N Circ Res; 2015 Apr; 116(8):1284-6. PubMed ID: 25858058 [No Abstract] [Full Text] [Related]
20. A novel, potent, and selective inhibitor of cardiac late sodium current suppresses experimental arrhythmias. Belardinelli L; Liu G; Smith-Maxwell C; Wang WQ; El-Bizri N; Hirakawa R; Karpinski S; Li CH; Hu L; Li XJ; Crumb W; Wu L; Koltun D; Zablocki J; Yao L; Dhalla AK; Rajamani S; Shryock JC J Pharmacol Exp Ther; 2013 Jan; 344(1):23-32. PubMed ID: 23010360 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]